创伤与急诊电子杂志
創傷與急診電子雜誌
창상여급진전자잡지
Journal of Trauma and Emergency (Electronic Version)
2015年
2期
13-16
,共4页
2型糖尿病%冠心病%半乳糖凝集素-3%生物学标记物
2型糖尿病%冠心病%半乳糖凝集素-3%生物學標記物
2형당뇨병%관심병%반유당응집소-3%생물학표기물
Type 2 diabetes%Coronary artery disease%Galectin-3%Biomarker
目的：本研究旨在探讨血清半乳糖凝集素-3水平与2型糖尿病患者合并冠心病的相关性。方法本研究共纳入177例2型糖尿病患者，根据患者是否罹患冠心病将所有患者分为冠心病组(D-CAD+,n=65)及非冠心病组(D-CAD-,n=112)，另选取单纯冠心病患者(CAD+,n=73)及健康成人(ND,n=50)作为对照组。采用酶联免疫吸附(ELISA)法测量各组血清半乳糖凝集素-3水平。结果D-CAD+组患者血清Gal-3水平表达最高(10.27±2.53)ng/ml，其次为CAD+组(5.72±0.64)ng/ml，再次为D-CAD-组(2.64±0.36)ng/ml，ND组表达最低(1.17±0.21)ng/ml。D-CAD+组患者血清Gal-3表达水平较CAD+组显著升高，而后者显著高于D-CAD-组，同时上述三组均高于ND组，差异均有统计学意义(P<0.05)。多元Logistic回归分析显示高血清半乳糖凝集素-3水平与2型糖尿病患者存在冠心病呈独立相关(优势比2.375,95%可信区间1.258～3.952；P<0.01)。结论血清半乳糖凝集素-3水平是预测2型糖尿病患者合并冠心病的独立危险因子，血清半乳糖凝集素-3有望可能成为预测2型糖尿病患者发生冠心病风险的重要的生物学标记物。
目的：本研究旨在探討血清半乳糖凝集素-3水平與2型糖尿病患者閤併冠心病的相關性。方法本研究共納入177例2型糖尿病患者，根據患者是否罹患冠心病將所有患者分為冠心病組(D-CAD+,n=65)及非冠心病組(D-CAD-,n=112)，另選取單純冠心病患者(CAD+,n=73)及健康成人(ND,n=50)作為對照組。採用酶聯免疫吸附(ELISA)法測量各組血清半乳糖凝集素-3水平。結果D-CAD+組患者血清Gal-3水平錶達最高(10.27±2.53)ng/ml，其次為CAD+組(5.72±0.64)ng/ml，再次為D-CAD-組(2.64±0.36)ng/ml，ND組錶達最低(1.17±0.21)ng/ml。D-CAD+組患者血清Gal-3錶達水平較CAD+組顯著升高，而後者顯著高于D-CAD-組，同時上述三組均高于ND組，差異均有統計學意義(P<0.05)。多元Logistic迴歸分析顯示高血清半乳糖凝集素-3水平與2型糖尿病患者存在冠心病呈獨立相關(優勢比2.375,95%可信區間1.258～3.952；P<0.01)。結論血清半乳糖凝集素-3水平是預測2型糖尿病患者閤併冠心病的獨立危險因子，血清半乳糖凝集素-3有望可能成為預測2型糖尿病患者髮生冠心病風險的重要的生物學標記物。
목적：본연구지재탐토혈청반유당응집소-3수평여2형당뇨병환자합병관심병적상관성。방법본연구공납입177례2형당뇨병환자，근거환자시부리환관심병장소유환자분위관심병조(D-CAD+,n=65)급비관심병조(D-CAD-,n=112)，령선취단순관심병환자(CAD+,n=73)급건강성인(ND,n=50)작위대조조。채용매련면역흡부(ELISA)법측량각조혈청반유당응집소-3수평。결과D-CAD+조환자혈청Gal-3수평표체최고(10.27±2.53)ng/ml，기차위CAD+조(5.72±0.64)ng/ml，재차위D-CAD-조(2.64±0.36)ng/ml，ND조표체최저(1.17±0.21)ng/ml。D-CAD+조환자혈청Gal-3표체수평교CAD+조현저승고，이후자현저고우D-CAD-조，동시상술삼조균고우ND조，차이균유통계학의의(P<0.05)。다원Logistic회귀분석현시고혈청반유당응집소-3수평여2형당뇨병환자존재관심병정독립상관(우세비2.375,95%가신구간1.258～3.952；P<0.01)。결론혈청반유당응집소-3수평시예측2형당뇨병환자합병관심병적독립위험인자，혈청반유당응집소-3유망가능성위예측2형당뇨병환자발생관심병풍험적중요적생물학표기물。
Objective To explore whether serum galectin-3 (Gal-3) levels are associated with the presence of coronary artery disease (CAD) in patients with type 2 diabetes (DM2). Method A total of 177 patients with DM2 were enrolled in the present study. All the patients were classified as D-CAD+ (n=65) or D-CAD- (n=112) group based on the presence of CAD or not.73 patients with CAD and 50 healthy adults served as the control group. Serum Gal-3 levels were determined by enzyme-linked immunosorbent assay (ELISA).Result The highest serum Gal-3 expression level of (10.27±2.53)ng/ml was present in D-CAD+ patients, followed by the CAD+ patients with the level of (5.72±0.64)ng/ml and the D-CAD- patients with the level of (2.64 ±0.36)ng/ml, while the lowest one of (1.17±0.21)ng/ml was present in healthy adults. D-CAD+patients had significantly higher Serum Gal-3 levels than CAD+ patients, and the latter had significantly higher Serum Gal-3 levels than D-CAD- patients. Serum Gal-3 levels in all three groups above were significantly higher in healthy adults, which presented statistically significant differences (P<0.05).Multivariate logistic regression demonstrated that higher Gal-3 levels were independently associated with the presence of CAD (OR 2.375, 95% CI 1.258~3.952,P<0.01) in patients with DM2.Conclusion Serum Gal-3 is an independent risk factor for CAD in DM2 patients, which indicates that Gal-3 might be a useful biomarker for predicting the presence of CAD in patients with DM2.
